Investment Rating - The investment rating for the company is "Buy" (maintained) [6][14]. Core Insights - In 2024, the company achieved revenue of 10.494 billion yuan, a year-on-year decrease of 10.04%, while the net profit attributable to shareholders was 1.371 billion yuan, an increase of 8.69% year-on-year. The first quarter of 2025 saw revenue of 2.038 billion yuan, down 3.46% year-on-year, and a net profit of 12 million yuan, down 92.69% year-on-year [3][12][19]. - The company's retail brand revenue declined by 10.46% year-on-year, while the Milan brand continued to grow in lower-tier markets with an increase of 8.09% year-on-year. The integrated channel showed strong growth with a 16.22% year-on-year increase [3][12][14]. - The company sold its stake in Minsheng Securities, generating investment income that affected the apparent performance. The "old-for-new" policy in 2025 is expected to boost home consumption, leading the industry to accelerate its transformation towards the stock market [3][12][14]. Financial Performance Summary - For 2024, the company reported a revenue of 10.494 billion yuan, with a year-on-year growth rate of -10.04%. The net profit attributable to shareholders was 1.371 billion yuan, with a growth rate of 8.69% [15][30]. - The projected revenues for 2025, 2026, and 2027 are 11.232 billion yuan, 12.099 billion yuan, and 13.090 billion yuan, respectively, with year-on-year growth rates of 7.03%, 7.72%, and 8.19% [14][15]. - The earnings per share (EPS) for 2025, 2026, and 2027 are expected to be 1.34 yuan, 1.49 yuan, and 1.63 yuan, respectively, with a three-year compound annual growth rate (CAGR) of 4.59% [14][15].

证券研究报告·A 股公司简评 计算机 核心观点 2024 年，公司营收 264.15 亿元，同比增长 9.78%；归母净利润 7.49 亿元，同比增长 112.11%；扣非归母净利润 3.53 亿元，同比 增长 105.60%。25Q1，公司营收 59.27 亿元，同比下降 5. 79%； 归母净利润 0.84 亿元，同比下降 69.64%。受益于国内信创打印 机出货持续增长，一带一路推动下海外需求旺盛，叠加公司 A 3 打 印机销量实现高速增长，预计公司 2025-2027 年营业收入分别为 156.76/193.94/237.53 亿元，同比分别变动-40.65%/23.72%/ 22.48%，归母净利润为 15.60/22.12/29.90 亿元，同比分别增长 108.28%/41.73%/35.21%，对应 PE 20/14/10 倍，维持"买入"评 级。 事件 2024 年，公司营收 264.15 亿元，同比增长 9.78%；归母净利润 7.49 亿元，同比增长 112.11%；扣非归母净利润 3.53 亿元，同比 增长 105.60%。2025 年第一季度，公司营收 59.27 亿元，同比下 降 ...

盈利能力方面，24 年公司毛利率为 18.64%，同比下降 5.15pct；24Q4 公司毛利率为18.91%，同比下降4.20pct。25Q1公司毛利率为16.27%， 同比下降 8.53pct。24 年公司毛利率下降主要系期间海运费大幅上涨 一段时期。期间费用方面，24 年公司期间费用率为 13.38%，同比下 降 2.99pct ，销售 / 管 理 / 研 发 / 财 务 费 用 率 分 别 为 2025 年 05 月 18 日 恒林股份(603661.SH) 利润短期承压， 跨境电商顺利扩张 事件：恒林股份发布 2024 年年度报告和 2025 年一季报。24 年 公司实现营业收入 110.29 亿元，同比增长 34.59%；归母净利润 2.63 亿元，同比下降 0.02%；扣非后归母净利润 2.81 亿元，同比 增长 19.45%。24Q4 公司实现营业收入 32.18 亿元，同比增长 33.03%；归母净利润-0.03 亿元，同比增长 97.16%；扣非后归母 净利润 0.16 亿元，同比增长 115.81%。25Q1 公司实现营业收入 26.54 亿元，同比增长 12.74%；归母净利润 0.5 ...

上 市 公 司 基础化工 ——行业底部凸显盈利韧性，兼具高成长与高分红 报告原因：有业绩公布需要点评 增持（维持） | 市场数据： | 2025 年 05 月 16 日 | | --- | --- | | 收盘价（元） | 5.16 | | 一年内最高/最低（元） | 8.28/4.90 | | 市净率 | 1.3 | | 股息率%（分红/股价） | 5.81 | | 流通 A 股市值（百万元） | 17,123 | | 上证指数/深证成指 | 3,367.46/10,179.60 | | 注："股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 03 月 31 日 | | --- | --- | | 每股净资产（元） | 3.98 | | 资产负债率% | 44.77 | | 总股本/流通 A 股（百万） | 3,739/3,318 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： 05-16 06-16 07-16 08-16 09-16 10-16 11-16 12-16 01-16 02-16 03-16 04-16 05-16 -40% -30 ...

核心观点 盈利预测与投资建议 ⚫ 考虑到原材料价格波动，我们适当下调公司毛利率并上调部分费用率预测，并调整 公司 2025-2027 年每股收益预期分别为 1.38/1.60/1.84 元（原 25 年预测 2.03 元）， 按照 25 年可比公司平均 16 倍市盈率，给予目标价 22.08 元，维持买入评级。 风险提示：原材料价格上涨、国内外需求下滑、海外基地投产进度不及预期、国内供 给增长加快、业务结构调整不及预期、关税政策变化、汇率波动。 玲珑轮胎 601966.SH 公司研究 | 年报点评 季度业绩承压，拟建海外第三基地 品牌力强者，整装待发再启航 2024-04-09 公司主要财务信息 | | 买入 （维持） | | --- | --- | | 股价（2025年05月16日） | 14.75 元 | | 目标价格 | 22.08 元 | | 52 周最高价/最低价 | 21.91/14.13 元 | | 总股本/流通 A 股（万股） | 146,350/146,350 | | A 股市值（百万元） | 21,587 | | 国家/地区 | 中国 | | 行业 | 石油化工 | | 报告发布日期 | ...

2025 年 05 月 18 日 公司点评 增持/首次 川金诺(300505) 昨收盘:18.79 2024 年业绩大幅改善，2025Q1 盈利同比高增 走势比较 (40%) (28%) (16%) (4%) 8% 20% 24/5/20 24/7/31 24/10/11 24/12/22 25/3/4 25/5/15 证券分析师：王亮 E-MAIL：wangl@tpyzq.com 分析师登记编号：S1190522120001 证券分析师：王海涛 E-MAIL：wanght@tpyzq.com 分析师登记编号：S1190523010001 事件：公司近期发布 2024 年报及 2025 年一季报，2024 年实现营 业收入 32.1 亿元，同比上升 18.3%；归母净利润 1.76 亿元，实现扭 亏；其中 2024Q4 实现营收 10.1 亿元，同比上升 26.5%；归母净利润 6560 万元，同比上升 294.4%；2025 年一季度实现营收 7.21 亿元，同 比增长 24.00%；归属于上市公司股东的净利润为 7202.18 万元，同比 增长 253.41%。 2024 年业绩大幅改善，柔性生产优势、区 ...

[Table_Title] 证券研究报告 / 公司动态报告 海外业务快速增长、固态电池提升空间 报告摘要： [Table_Summary] 公司海外业务持续高增长。公司持续拓展海外市场，不断提升海外客户 多元化程度。同时，公司持续优化全球网络和资源配置，不断完善本土 化的服务团队和生产制造能力，快速响应客户需求。2024 年，公司海外 业务收入达到 28.31 亿元，同比增加 26.31%，收入占比提升至 23.88%， 毛利率同比提升至 39.32%。公司 2022 年和 2023 年海外收入为 11.95 亿 元和 22.41 亿元，收入占比分别为 8.58%和 13.48%。公司海外业务持续 高增长，反应了公司全球化战略加速推进，体现公司产品较强的国际竞 争力。 固态电池产线提升空间。公司聚焦行业前沿工艺趋势，实现了在全固态 电池领域整线关键技术的突破，2024 年重磅推出全固态整线解决方案， 打通了全固态电池制造工艺环节。该方案覆盖全固态电极制备、全固态 电解质膜制备及复合设备、裸电芯组装到致密化设备、高压化成分容等 全固态电池制造关键设备，在电芯结构缓冲件成形、无隔膜叠片、连续 致密化、高压化成分容 ...

丨证券研究报告丨 公司研究丨点评报告丨德邦股份（603056.SH） [Table_Title] 业绩阶段性承压，经营调优成效可期 ——德邦股份 2024 年报及 2025 年一季报点评 报告要点 [Table_Summary] 2024 年，公司营收同比增长 11.3%，其中，快运/快递/其他业务营收分别+13.0%/- 19.7%/+34.6%；由于整车、大票、供应链等高运费低人工的业务占比提升，公司为保证运输稳 定持续投入运输资源，毛利率有所承压；2024 年，公司归母净利润同比增长 15.4%。25Q1， 公司实现营收同比增长 12.0%，但由于产品结构调整，拖累盈利表现，归母净利润转亏。作为 稀缺性的全网型快运企业，看好公司市场份额持续提升，以及与京东物流快运业务的网络融合 效果。 分析师及联系人 [Table_Author] SAC：S0490512020001 SAC：S0490519060002 SAC：S0490524120001 SFC：BQK468 韩轶超 鲁斯嘉 胡俊文 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 德邦股份（60305 ...

Investment Rating - The report maintains a "Buy" rating for China Chemical [4] Core Views - The domestic production of adiponitrile is accelerating, and the demand for civilian silk is expected to be released, indicating a broad growth space in the future. The nylon 66 (PA66) is one of the most widely used nylon products, with advantages such as high strength, good wear resistance, and excellent lubrication. However, the domestic demand for nylon 66 has not been fully released due to the influence of domestic civilian wire drawing technology. Currently, the application ratio of nylon 66 in civilian silk is low (13%). If breakthroughs in civilian silk technology are achieved, it is expected to partially replace the nylon 6 market [12][19]. Summary by Sections Production and Cost Analysis - The current production cost of adiponitrile is approximately 11,600 yuan/ton, with the main raw materials being butadiene, natural gas, and liquid ammonia. As of May 16, 2025, the prices are 11,000 yuan/ton for butadiene, 3.91 yuan/cubic meter for natural gas, and 2,430 yuan/ton for liquid ammonia [2][16][17]. Profitability and Financial Projections - The profitability of the adiponitrile project is expected to be good after reaching full production, with high profit elasticity anticipated. The report estimates the break-even price for the product under different capacity utilization scenarios. At 150% design capacity utilization (30,000 tons/year), the break-even price is 17,700 yuan/ton; at 100% (20,000 tons/year), it is 19,000 yuan/ton; and at 50% (10,000 tons/year), it is 22,900 yuan/ton. The average price of domestic adiponitrile since May is approximately 22,200 yuan/ton, close to the break-even line at 50% utilization [3][19]. Future Earnings Estimates - The report forecasts the company's net profit attributable to shareholders for 2025-2027 to be 6.4 billion, 7.3 billion, and 8.1 billion yuan, respectively, with year-on-year growth rates of 12.7%, 13.4%, and 11.2%. The current stock price corresponds to P/E ratios of 7.5, 6.6, and 6.0 for the respective years [19]. Investment Recommendation - Given the significant earnings elasticity of the company's industrial projects, accelerated execution of overseas orders, benefits from the acceleration of coal chemical investments, high profitability quality, ample cash flow, and potential for increased dividends, the report continues to recommend a "Buy" rating [19].

Investment Rating - The report maintains a "Recommended" rating for the company, with a target price of 21 yuan [2][9]. Core Views - The medical device sector faced temporary pressure, while the pharmaceutical equipment segment showed steady growth. The company reported a slight increase in total revenue for 2024, reaching 10,021 million yuan, up by 0.09% year-on-year, and a net profit of 692 million yuan, up by 5.75% year-on-year [2][9]. - The company plans to distribute a cash dividend of 0.25 yuan per share (before tax) to all shareholders [2]. Financial Performance Summary - **2024 Financial Results**: - Total revenue: 10,021 million yuan - Net profit attributable to the parent: 692 million yuan - Non-recurring net profit: 623 million yuan - Q4 2024 revenue: 2,597 million yuan (down 3.63% QoQ) - Q1 2025 revenue: 2,308 million yuan (down 8.74% YoY) [2][4]. - **Revenue Breakdown**: - Medical device revenue: 3,735 million yuan (down 10.37%) - Pharmaceutical equipment revenue: 2,171 million yuan (up 12.90%) - Medical trade revenue: 3,125 million yuan (up 8.04%) - Medical services revenue: 834 million yuan (down 9.51%) [9]. - **Profitability Metrics**: - Overall gross margin for 2024: 26.06% (down 1.31 percentage points) - Net profit margin for 2024: 6.90% (up 0.14 percentage points) [9]. Future Projections - **Earnings Forecast**: - Expected net profit for 2025: 798 million yuan (up 15.4%) - Expected net profit for 2026: 928 million yuan (up 16.2%) - Expected net profit for 2027: 1,027 million yuan (up 10.7%) [4][9]. - **Earnings Per Share (EPS)**: - 2025: 1.32 yuan - 2026: 1.53 yuan - 2027: 1.69 yuan [4][9]. - **Valuation Ratios**: - Price-to-Earnings (P/E) ratio for 2025: 12 times - Price-to-Book (P/B) ratio for 2025: 1.1 times [4][9].